Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00764673 · ClinicalTrials.gov registry record · Phase 4

The 3DKnee™ System: A Post-Market Study

A Phase 4 study, sponsored by Encore Medical, L.P..

Completed
Registry status
Phase 4
Development phase
71
Enrollment target

NCT00764673: Completed Phase 4 study, sponsored by Encore Medical, L.P..

NCT00764673 is a Phase 4 study that has completed, run by Encore Medical, L.P.. The registered enrollment target is 71 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00764673, a Phase 4 study, has completed, sponsored by Encore Medical, L.P..

COMPLETED
Registry status
Phase 4
Development phase
71 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the survivorship and efficacy of the Encore 3DKnee™ system in a group of patients who will receive the 3DKnee™ as a primary (first) orthopedic implant in the knee. Each knee will be designated as a separate subject and followed for a period of 2 years.

Primary Outcome

The Knee Society Score includes a knee rating and function score. This evaluation covers the knee rating score with three main parameters of pain, stability and range of motion and that flexion contracture, extension lag and misalignment should be dealt with as deductions. Thus, 100 points will be obtained by a well-aligned knee with no pain, 125 degrees of motion, and negligible anteroposterior and mediolateral instability. 50 points are allotted for pain, 25 for stability, and 25 for range of

Interventions

  • DEVICE 3DKnee

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2006-10
Est. Completion 2010-10
Phase Phase 4
Encore Medical, L.P.

16 total trials

What the finished NCT00764673 record still lists

NCT00764673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower).

The record links to 0 conditions, and to 1 intervention - of which 3DKnee is the first listed.

NCT00764673 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00764673 about?

NCT00764673 is a clinical study titled "The 3DKnee™ System: A Post-Market Study". The purpose of this study is to evaluate the survivorship and efficacy of the Encore 3DKnee™ system in a group of patients who will receive the 3DKnee™ as a primary (first) orthopedic implant in the knee. Each knee will be designated as a separate subject and followed for a period of 2 years.

What is the current status of trial NCT00764673?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 71 participants. The study started on 2006-10. Estimated completion is 2010-10.

What interventions are being tested in trial NCT00764673?

The interventions under investigation include: 3DKnee (DEVICE).

Who is sponsoring clinical trial NCT00764673?

This trial is sponsored by Encore Medical, L.P., which has 16 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00764673's enrollment target sits among peer trials

71 1040th of 2000 higher than 958 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05452889 · 71 participants · Early Phase 1

    PET Image in PAH Patients

  • NCT05766943 · 71 participants · NA

    Reduction of Myopotential Interference With Smart Pass in S-ICD Patients

  • NCT06229678 · 71 participants · Early Phase 1

    Ketones, SGLT2, HFrEF

  • NCT06377566 · 71 participants · Phase 2

    A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00764673, the US trial registry maintained by the National Library of Medicine. NCT00764673 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.